News and Trends 9 Jan 2023 Boehringer Ingelheim and 3T Biosciences to develop next-generation cancer immunotherapies Boehringer Ingelheim and 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune […] January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 STALICLA signs agreement with Novartis on neurodevelopmental disorders STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, has entered into an exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder and neurodevelopmental disorders (NDDs). Mavoglurant has previously been tested in more than 1,800 patients and demonstrated a good safety and […] January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 Cancer Research UK and Turbine to partner on program Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK, has announced that it is partnering with Turbine AI, a tech-enabled biotech leveraging its proprietary Simulated Cell platform to solve complex diseases. The partnership will utilize Turbine AI’s platform to identify target patient populations […] January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 Hummingbird Bioscience and Synaffix to develop ADC program Synaffix B.V. and Hummingbird Bioscience have entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation antibody drug conjugate (ADC) program using Synaffix technology. Synaffix is a biotechnology company focused on commercializing its clinical-stage platform technology for the development of ADCs. Hummingbird Bioscience is a data-driven precision biotherapeutics company using […] January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Dec 2022 Watch: Zoetis looks for partnerships at BioFIT Animal health company, Zoetis, has a pipeline of medicines, vaccines, diagnostics and technologies for livestock and pets. Active in more than 100 countries, Zoetis generated revenue of $7.8 billion in 2021, and has approximately 12,100 employees. The company recently announced a collaboration with the partners of the Pastoral Greenhouse Gas Research Consortium, and the New […] December 29, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Mersana Therapeutics and Merck to develop novel ADCs Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen antibody drug conjugates (ADCs) directed against up to two targets. Immunosynthen, Mersana Therapeutics’ proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both […] December 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Merck and Kelun-Biotech collaborating on seven ADC cancer candidates Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer. “Advances in ADC technologies are yielding a new generation of candidates designed to more […] December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 InSitu Biologics and Mayo Clinic to co-develop anti-cancer therapeutics InSitu Biologics, Inc. has entered into an agreement with the Mayo Foundation for Medical Education and Research to further develop its prolonged-release drug delivery technology for anti-cancer therapeutics. The company has developed an industry-leading platform technology for loading large doses of a variety of medications into a localized delivery matrix. Once injected, medication elutes from […] December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2022 Japanese companies look to reduce environmental impact Japanese companies Astellas Pharma Inc., Eisai Co., Ltd., Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited have agreed a collaboration to reduce the environmental impact of pharmaceutical packaging. Based on the agreement, the four companies will aim to promote the use of more environmentally-friendly packaging for pharmaceutical products by sharing knowledge on packaging technologies […] December 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The efforts will utilize Ethris’ mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms. The collaboration is founded on a $42 million award to DIOSynVax by the […] December 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Pfizer diabetes and obesity study triggers Sosei Heptares windfall Sosei Group Corporation has been notified by Pfizer that the first subject in a phase 2 clinical trial has been dosed with Pfizer’s candidate PF-07081532. This triggers a $10 million payment to Sosei Heptares. PF-07081532 is a once-daily, next-generation oral small molecule GLP-1 receptor agonist in development for the treatment of type 2 diabetes and obesity. […] December 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Ori Biotech and Inceptor Bio partner on solid tumor cell therapy Cell and gene therapy (CGT) company Ori Biotech, and cell therapy firm Inceptor Bio have announced a new partnership. The deal will utilize Ori Biotech’s manufacturing platform technology to support initial process development through scale-up for manufacturing of Inceptor’s novel CAR-M, CAR-T and CAR-NK programs. Inceptor Bio is the third partner to join Ori’s LightSpeed […] December 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email